|
Volumn 44, Issue 2, 2000, Pages 138-152
|
Clinical and economic outcomes assessment in nuclear cardiology
a a a a |
Author keywords
Health care costs; Heart radionuclide imaging; Nuclear medicine, economics
|
Indexed keywords
ACETYLSALICYLIC ACID;
BETA ADRENERGIC RECEPTOR BLOCKING AGENT;
DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;
STATIN;
CARDIOLOGY;
CLINICAL RESEARCH;
ECONOMIC EVALUATION;
EVIDENCE BASED MEDICINE;
HEALTH CARE COST;
HEALTH CARE QUALITY;
HEART CATHETERIZATION;
HEART DISEASE;
HEART MUSCLE REVASCULARIZATION;
HORMONE SUBSTITUTION;
HUMAN;
IMAGING;
NUCLEAR MEDICINE;
OUTCOMES RESEARCH;
PATIENT CARE;
POPULATION RESEARCH;
QUALITY OF LIFE;
RESOURCE ALLOCATION;
REVIEW;
RISK MANAGEMENT;
SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;
ANGIOGRAPHY;
CORONARY DISEASE;
COST CONTROL;
COST-BENEFIT ANALYSIS;
COSTS AND COST ANALYSIS;
DATABASES;
EVIDENCE-BASED MEDICINE;
HEART DISEASES;
HUMANS;
MULTICENTER STUDIES;
NUCLEAR MEDICINE;
OUTCOME ASSESSMENT (HEALTH CARE);
POPULATION SURVEILLANCE;
QUALITY OF HEALTH CARE;
QUALITY OF LIFE;
RANDOMIZED CONTROLLED TRIALS;
RISK ASSESSMENT;
TECHNOLOGY, RADIOLOGIC;
TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;
|
EID: 0033890230
PISSN: 11243937
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
Times cited : (11)
|
References (39)
|